Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coretox
- Development stage
- Unknown
- Lead developer
- Medytox
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal, Intramuscular
01
Overview
Coretox is a protein-free, animal-component-free formulation of botulinum toxin type A (150 kDa) developed by Medytox. Unlike conventional botulinum toxin formulations, Coretox is purified to remove accessory complexing proteins, leaving only the active 150 kDa neurotoxin. This design is intended to reduce the risk of immunogenicity and antibody resistance during repeated treatments. Additionally, Coretox is manufactured without human serum albumin (HSA) or other animal-derived components, utilizing polysorbate 20, L-methionine, and sucrose as stabilizers to eliminate the risk of blood-derived pathogen transmission. It is approved in South Korea for aesthetic indications, such as the temporary improvement of moderate to severe glabellar wrinkles, and therapeutic indications, including upper limb spasticity.
- Brand names
- Coretox
- Other names
- Clostridium botulinum toxin type Abotulinum toxin type A
02
Targets
SV2A (Synaptic vesicle glycoprotein 2A)SV2B (Synaptic vesicle glycoprotein 2B)SV2C (Synaptic vesicle glycoprotein 2C)SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on Coretox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coretox.